| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.44▼ | 1.45▼ | 1.45▼ | 1.43▲ | 1.46▼ |
| MA10 | 1.43▼ | 1.43▼ | 1.42▼ | 1.45▼ | 1.46▼ |
| MA20 | 1.46▼ | 1.51▼ | 1.52▼ | 1.48▼ | 1.60▼ |
| MA50 | 1.51▼ | 1.44▼ | 1.42▲ | 1.48▼ | 1.83▼ |
| MA100 | 1.43▼ | 1.50▼ | 1.51▼ | 1.62▼ | 1.94▼ |
| MA200 | 1.58▼ | 1.63▼ | 1.64▼ | 1.82▼ | 2.35▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | -0.008▼ | -0.011▼ | -0.006▼ | -0.004▼ |
| RSI | 40.844▼ | 44.501▼ | 45.611▼ | 48.376▼ | 43.102▼ |
| STOCH | 80.723▲ | 69.864 | 59.698 | 25.108 | 40.611 |
| WILL %R | -45.249 | -71.428 | -77.465▼ | -77.500▼ | -62.500 |
| CCI | 7.935 | -17.263 | -33.583 | -25.553 | -44.473 |
|
Thursday, April 23, 2026 01:03 AM
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced ...
|
|
Wednesday, April 22, 2026 10:00 PM
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target ...
|
|
Thursday, April 16, 2026 08:00 PM
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/26 | 1.485 | 1.54 | 1.44 | 1.44 | 10,333 |
| 30/04/26 | 1.43 | 1.47 | 1.42 | 1.44 | 43,703 |
| 29/04/26 | 1.45 | 1.49 | 1.45 | 1.48 | 67,428 |
| 28/04/26 | 1.41 | 1.43 | 1.3901 | 1.40 | 11,989 |
| 27/04/26 | 1.39 | 1.40 | 1.36 | 1.40 | 9,926 |
| 24/04/26 | 1.35 | 1.42 | 1.35 | 1.41 | 26,674 |
| 23/04/26 | 1.44 | 1.45 | 1.37 | 1.37 | 4,039 |
| 22/04/26 | 1.46 | 1.47 | 1.39 | 1.43 | 25,444 |
| 21/04/26 | 1.5301 | 1.56 | 1.51 | 1.51 | 7,893 |
| 20/04/26 | 1.63 | 1.65 | 1.57 | 1.59 | 13,777 |
|
|
||||
|
|
||||
|
|